<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04299022</url>
  </required_header>
  <id_info>
    <org_study_id>CR-20-002</org_study_id>
    <nct_id>NCT04299022</nct_id>
  </id_info>
  <brief_title>Safety, Efficacy, &amp; Use of ViviGen Cellular Bone Matrix Allograft in Orthopaedic Fracture Care</brief_title>
  <official_title>Safety, Efficacy, &amp; Use of ViviGen Cellular Bone Matrix Allograft in Orthopaedic Fracture Care: A Multi-Center Prospective Registry and Retrospective Data Collection Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LifeNet Health</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LifeNet Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective registry and retrospective data collection study to assess the efficacy and
      safety of Vivigen Cellular Bone Matrix (Vivigen) in orthopaedic trauma patients who require
      bone grafting in the acute, delayed, non-union fracture as well as use in fusion procedure
      settings.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prospective registry study and retrospective data collection study is planned to assess
      the efficacy and safety of Vivigen Cellular Bone Matrix (Vivigen) in orthopaedic trauma
      patients who require bone grafting in the acute, delayed, non-union fracture as well as use
      in fusion procedure settings.

      Patients will be assessed at hospital discharge, 6 weeks, 3 months, 6 months, 12 months and
      24 months after treatment of a traumatic fracture with a bone graft.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 15, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>24 Months</target_duration>
  <primary_outcome>
    <measure>Reintervention Rate</measure>
    <time_frame>24 months</time_frame>
    <description>the proportion of patients requiring secondary intervention (return to the operating room) within twelve months after definitive wound closure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fusion Rate</measure>
    <time_frame>24 months</time_frame>
    <description>Acute fracture, delayed union or nonunion rate as assessed with radiographs at 6 weeks, 3 months, 6 months, 12 months and 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcome Measurement Information System (PROMIS) Scores</measure>
    <time_frame>24 months</time_frame>
    <description>Patient reported outcome measures will be measured via PROMIS scoring tool (mental and physical). The PROMIS uses a T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. For PROMIS measures, higher scores equals more of the concept being measured (e.g., more Fatigue, more Physical Function). Thus a score of 60 is one standard deviation above the average referenced population.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Fractures, Bone</condition>
  <condition>Nonunion of Fracture</condition>
  <condition>Fractures, Open</condition>
  <condition>Fractures, Ununited</condition>
  <condition>Fracture, Tibial</condition>
  <condition>Fracture of Femur</condition>
  <condition>Fracture Arm</condition>
  <arm_group>
    <arm_group_label>Prospective Registry</arm_group_label>
    <description>Treatment for diagnoses of long bone non-union involving the tibia or femur and other nonunion diagnosis (i.e. clavicle, humerus, and femur) with Vivigen Cellular Bone Matrix</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Retrospective Data Collection</arm_group_label>
    <description>Treatment of diagnoses of long bone non-union involving the tibia or femur and other nonunion diagnosis (i.e. clavicle, humerus, and femur) with adjunct bone graft utilized in the acute, delayed, non-union and fusion settings.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vivigen Cellular Bone Matrix</intervention_name>
    <description>Allograft bone matrix</description>
    <arm_group_label>Prospective Registry</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Prospective data will be collected for up to 250 subjects across up to 7 academic medical
        centers that will receive Vivigen Cellular Bone Matrix for treatment of a fracture.
        Retrospective data will be collected for up to an additional 250 subjects that received a
        bone graft adjunct for treatment of a fracture.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Prospective Cohort Inclusion Criteria:

          -  Any skeletally mature patient treated with Vivigen bone graft in the setting of an
             acute fracture, delayed, non-union or fusion setting will be eligible for inclusion.

        Retrospective Cohort Inclusion Criteria:

        - Any skeletally mature patient treated with adjunct bone graft in the setting of an acute
        fracture, delayed, non-union or fusion setting will eligible for inclusion.

        Prospective Cohort Exclusion Criteria:

          1. Patients unable to understand either an English or Spanish consent will be excluded.

          2. Patients unable to consent secondary to dementia and/or other mental/psychiatric
             diagnoses will be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Kimberly Dorsch</last_name>
    <phone>757-609-4378</phone>
    <email>kimberly_dorsch@lifenethealth.org</email>
  </overall_contact>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 4, 2020</study_first_submitted>
  <study_first_submitted_qc>March 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2020</study_first_posted>
  <last_update_submitted>March 6, 2020</last_update_submitted>
  <last_update_submitted_qc>March 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fracture</keyword>
  <keyword>nonunion</keyword>
  <keyword>allograft</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Fractures, Ununited</mesh_term>
    <mesh_term>Femoral Fractures</mesh_term>
    <mesh_term>Fractures, Open</mesh_term>
    <mesh_term>Tibial Fractures</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

